Regenerative Medicines: Bone and Joint Applications

SUMMARY

INTRODUCTION

OBJECTIVES AND GOALS OF STUDY

Regenerative medicine refers to technologies that repair or replace diseased or defective tissuesor organs. The main types of regenerative medicine utilize products naturally occurring in the body, such as genes and proteins (antibodies, growthfactors, hormones); cells and tissues; embryonic stem cells, and biomaterials. At present, most regenerative medicines on the market fall into thefirst category and include protein-based drugs and therapies containing human cells. However, there are a few products based on tissue engineering.This technology, which promises to be the most exciting and fastest growing sector of regenerative medicine in the near future, is the primary focusof this report. Tissue engineering technologies discussed include matrices and scaffolds, in vitro and in vivo technologies, and novel materials,which include those utilizing nanotechnology (atomic-scale engineering) of inorganic substances that meld with human tissues.

This report focuseson the bone- and joint-related applications of and markets for the various types of regenerative medicine currently available and projected to beintroduced during the forecast period (2001 to 2007). Market drivers discussed include an increase in diseases and disorders that will benefit fromthese products, primarily arthritis, osteoporosis, and various types of bone and joint trauma (hip fractures, knee injuries, etc.); increasing use ofnonautograft products by physicians; and innovative devices that incorporate bone- and cartilage-growth stimulating agents in a regenerativeappliance. Products discussed include bone and cartilage grafting and regenerative products derived from autologous, allogeneic and synthetic sourcesas well as electronic bone growth stimulators and regenerative cartilage products. Profiles of leading and emerging companies in the bone and jointregenerative medicine markets are provided, along with analysis of the current and future positioning of their products and businesses in this activeand rapidly changing market.

CONTRIBUTION OF THE STUDY AND FOR WHOM

The aim of this report is to provide an overview ofregenerative medicine products available and emerging for the treatment of diseases and disorders of the bones and joints.

The information andanalysis presented are an important asset in decision-making for managers involved in business development, marketing, market research, productdevelopment, mergers and acquisitions, licensing, business management, investment banking and deal creation, and to consultants to the pharmaceuticaland biotechnology industries. The study provides a comprehensive analysis of the current markets for regenerative medicine products for bones andjoints, relevant applications, and the potential of products in development.

STUDY SCOPE AND FORMAT

• The scope of the study is worldwide. The Overview section provides a background of the demographics underlying the market for bone and jointproducts, a definition of regenerative medicine and the technologies involved, and a discussion of regenerative products in development forapplications other than bones and joints.
• The Applications section describes the leading bone and joint diseases and disorders applicable to regenerative technologies, includingincidence and current methods of treatment.
• The section on Products provides extensive descriptions and analysis (including comparative analysis) of regenerative products used to treatbone and joint disorders as well as discussion of products in development.
• The section on Industry provides a discussion of regulatory issues affecting regenerative medicine products as well as recent bankruptcies amongcompanies supplying regenerative products and the reasons for their financial difficulties.
• The Company Profiles section provides a concise exploration of leading and emerging companies in the area of regenerative products for bones andjoints, including product introductions, patents, and overall business strategies.

METHODOLOGY

The base year for this study is 2002. Figures are based on revenue figures at the manufacturer's level and areprojected at 2002 dollar values, that is, inflation is not computed into the projection figures.

Information to prepare this study was derivedfrom information provided by chief executive officers, marketing strategists, research executives and others at leading companies involved in theregenerative medicine market. Data was accessed from government agencies and regulatory bodies that monitor and/or regulate medical devices. Searchesof secondary material such as company annual reports and 10Ks, journal articles, prospectus assessments, government resources and data from healthcareinstitutions were also conducted.

INFORMATION SOURCES

The information and analysis presented in this report are based on anextensive survey of the biotechnology and pharmaceutical industries as well as a detailed examination of published literature and reports obtainedfrom regulatory authorities, medical research institutions, pharmaceutical trade associations and national and world health organizations.

TABLE OF CONTENTS

• OBJECTIVES AND GOALS OF STUDY
• CONTRIBUTION OF THE STUDY AND FOR WHOM
• STUDY SCOPE AND FORMAT
• METHODOLOGY
• INFORMATION SOURCES
• RELATED BCC WORK CREDENTIALS INCLUDING WORK DONE BY OTHER AUTHORS
• ANALYST CREDENTIALS
• BCC ON-LINE SERVICES
  • INTERNET

• Summary Table: THE U.S. MARKET FOR REGENERATIVE MEDICINE PRODUCTS USED IN BONE AND JOINT APPLICATIONS, THROUGH 2007 ($ MILLIONS)
• Summary Figure: THE U.S. MARKET FOR REGENERATIVE MEDICINE PRODUCTS USED IN BONE AND JOINT APPLICATIONS, 2001, 2002 AND 2007 ($ MILLIONS)

• THE GROWING MARKET FOR REGENERATIVE MEDICINE
• WHAT IS REGENERATIVE MEDICINE?
  • BIOLOGY-BASED MEDICINE
  • APPROACHES USED IN REGENERATIVE MEDICINE
  • HUMAN SUBSTANCES
  • CELLS AND TISSUES
  • Tissue Engineering
  • The Importance of Scaffolding in Tissue Engineering
  • Blood Vessel Scaffolding
  • Massachusetts General/MIT
  • Duke University
  • Advanced Tissue Sciences
  • EMBRYONIC STEM CELLS
  • Therapeutic Cloning
  • ADULT STEM CELLS-JUST AS GOOD AS EMBRYONIC STEM CELLS
  • Genzyme
  • University of Minnesota
  • Marketers of Adult Stem Cells
  • SETTING THE STAGE FOR REGENERATIVE MEDICINE TO TREAT BONE AND JOINT DISORDERS
  • NOVEL MATERIALS
  • GENE THERAPY
  • Gene Therapy Trials Targeting Bone and Joint Diseases and Disorders
  • Food and Drug Administration Halts Gene Therapy Trials
• THE USE OF BIOREACTORS IN REGENERATIVE MEDICINE
• THE IMPACT OF GENOMICS
• OTHER AREAS OF PROGRESS IN REGENERATIVE MEDICINE
  • CARDIOVASCULAR TECHNOLOGIES
  • Angiogenesis
  • Use of Angiogenesis in the Treatment of Heart Disease
  • Cardiac Cell Therapy
  • The Myocardial Patch
  • NEUROLOGICAL TECHNOLOGIES
  • Neurotransplantation in Stroke Patients
  • Embryonic Cell Transplant Therapy for Patients with Spinal Cord Injury
  • Use of Bone Morphogenic Proteins in the Treatment of Traumatic Spinal Cord Injury
  • SKIN TECHNOLOGIES
  • Skin Technologies (Continued)

• MAJOR DISEASES AND CONDITIONS AFFECTING BONES
  • OSTEOPOROSIS
  • Currently Available Products to Treat Osteoporosis
  • Bisphosphonates
  • Fosamax
  • Hormones
  • Evista
  • Forteo
  • Miacalcin
  • The Market for Products to Treat Osteoporosis
• Table 1 THE WORLDWIDE MARKET FOR DRUGS TO TREAT OSTEOPOROSIS, THROUGH 2007 ($ MILLIONS)
  • PAGET'S DISEASE
  • Currently Available Drugs to Treat Paget's Disease
  • Actonel
  • Aredia
  • Skelid
  • The Market for Products to Treat Paget's Disease
• Table 2 THE WORLDWIDE MARKET FOR DRUGS TO TREAT PAGET'S DISEASE, THROUGH 2007 ($ MILLIONS)
  • INJURIES AND DEGENERATIVE CONDITIONS
  • Hip Fractures
• Table 3 HIP FRACTURE VOLUMES, WORLDWIDE, THROUGH 2007
• Table 4 HIP FRACTURE VOLUMES, U.S., THROUGH 2007
  • TRADITIONAL TREATMENTS FOR BONE AND JOINT DISORDERS
• Figure 1 THE U.S. MUSCULOSKELETAL PRODUCTS MARKET, 2002
• Figure 2 THE U.S. RECONSTRUCTIVE DEVICE MARKET, 2002
  • Market Leaders
  • Joint Replacement Surgery
• Table 5 HIP REPLACEMENT PROCEDURE VOLUMES, U.S., THROUGH 2007
• Figure 3 HIP REPLACEMENT PROCEDURE VOLUMES, U.S., 2001, 2002 AND 2007
• Table 6 HIP REPLACEMENT PROCEDURE VOLUMES IN SIX STATES, 2001
• Table 7 THE HIP REPLACEMENT MARKET, WORLDWIDE, THROUGH 2007 ($ MILLIONS)
• Table 8 THE HIP REPLACEMENT MARKET, U.S., THROUGH 2007 ($ MILLIONS)
  • Knee Replacements
• Table 9 KNEE REPLACEMENT PROCEDURE VOLUMES, WORLDWIDE, THROUGH 2007
• Table 10 KNEE REPLACEMENT PROCEDURE VOLUMES, U.S., THROUGH 2007
• Figure 4 KNEE REPLACEMENT PROCEDURE VOLUMES, U.S., 2001, 2002 AND 2007
• Table 11 THE KNEE REPLACEMENT MARKET, WORLDWIDE, THROUGH 2007 ($ MILLIONS)
• Table 12 THE KNEE REPLACEMENT MARKET, U.S., THROUGH 2007 ($ MILLIONS)
• Table 13 THE MARKET FOR UNICONDYLAR KNEE REPLACEMENT, U.S., THROUGH 2007 ($ MILLIONS)
  • Spinal Fusion
  • Indications for Spinal Fusion
  • The Spinal Fusion Procedure
  • The Spinal Fusion Procedure (Continued)
  • Spinal Fusion Procedure Volumes
• Table 14 SPINAL FUSION PROCEDURE VOLUMES, WORLDWIDE, THROUGH 2007
• Table 15 SPINAL FUSION PROCEDURE VOLUMES, U.S., THROUGH 2007
• Figure 5 SPINAL FUSION PROCEDURE VOLUMES, U.S., THROUGH 2007
• Table 16 LUMBAR SPINAL FUSION PROCEDURE VOLUMES, U.S., THROUGH 2007
• Table 17 POSTERIOR LUMBAR SPINAL FUSION PROCEDURE VOLUMES, U.S., THROUGH 2007
• Table 18 CERVICAL SPINAL FUSION PROCEDURE VOLUMES, U.S., THROUGH 2007
  • The Market for Spinal Fusion Products
• Figure 6 THE U.S. SPINAL PRODUCTS MARKET, 2002
• Table 19 THE MARKET FOR INTERBODY FUSION DEVICE IMPLANTATION PROCEDURES, WORLDWIDE, THROUGH 2007 ($ MILLIONS)
• Table 20 INTERBODY FUSION DEVICE IMPLANTATION PROCEDURE VOLUMES, U.S., THROUGH 2007
  • TOTAL BONE REPLACEMENT
  • LIMB LENGTHENING
    • LIMB LENGTHENING (CONTINUED)
  • DISEASES AFFECTING JOINTS
    • OSTEOARTHRITIS
    • Osteoarthritis (Continued)
    • Glucosamine and Chondroitin for the Treatment of Osteoarthritis
    • RHEUMATOID ARTHRITIS
• Table 21 PREVALENCE OF RHEUMATOID ARTHRITIS, U.S., THROUGH 2007
  • Currently Available Drugs to Treat Rheumatoid Arthritis
  • Nonsteroidal Anti-inflammatory Drugs
  • COX-2 Inhibitors
  • Disease-Modifying Antirheumatic Drugs
  • Biological Response Modifiers to Treat Rheumatoid Arthritis
  • Enbrel
  • Kineret (Anakinra)
  • Antibody-based Drugs to Treat Rheumatoid Arthritis
  • Humira
  • Remicade
  • Downside of Currently Marketed Antibody Drugs
  • Antibody Drugs in Development to Treat Rheumatoid Arthritis
• Table 22 THERAPEUTIC ANTIBODY PRODUCTS IN PHASE II OR LATER DEVELOPMENT FOR THE TREATMENT OF RHEUMATOID ARTHRITIS
• Table 22 (CONTINUED)
  • The Market for DMARDs
• Table 23 THE MARKET FOR DISEASE-MODIFYING ANTI-ARTHRITIC DRUGS TO TREAT RHEUMATOID ARTHRITIS, WORLDWIDE, THROUGH 2007 ($ MILLIONS)
• Figure 7 THE MARKET FOR DISEASE-MODIFYING ANTI-ARTHRITIC DRUGS TO TREAT RHEUMATOID ARTHRITIS, WORLDWIDE, 2001, 2002 AND 2007 ($ MILLIONS)
  • Immunosuppressants
  • Drugs in Development to Treat Rheumatoid Arthritis
• Table 24 NUMBER OF 2003 TRIALS OF DRUGS TO TREAT RHEUMATOID ARTHRITIS BY MECHANISM OF ACTION

• REGENERATIVE TECHNOLOGIES
  • GENE- AND PROTEIN-BASED APPROACHES
  • Antibodies
  • The Importance of Antibody Drugs
  • Advantages of Monoclonal Antibody Drugs
  • Growth Factors
  • CELLS AND TISSUES
  • Tissue Engineering
  • Artificial Skin
  • Cartilage
  • Other Products
  • The Creation of Entire Organs
  • EMBRYONIC STEM CELLS
  • NOVEL MATERIALS/BIOMATERIALS
• REGENERATIVE PRODUCTS TO TREAT BONE DISEASES
  • OSTEOBIOLOGICS
  • Bone Grafts
• Table 25 BONE GRAFT PROCEDURE VOLUMES BY APPLICATION, U.S., THROUGH 2007
• Table 26 BONE GRAFT PROCEDURE VOLUMES BY TYPE OF GRAFT, U.S., THROUGH 2007
• Figure 8 BONE GRAFT PROCEDURE VOLUMES BY TYPE OF GRAFT, U.S., 2001, 2002 AND 2007
• Table 27 COMPARISON OF BONE GRAFT MATERIALS
• Table 28 TYPES OF SUBSTITUTE BONE GRAFTS
  • Autografts
  • Bioseed Grafts
  • Allografts
  • Allografts (Continued)
  • Risks Associated with Allografts
  • Demineralized Bone Matrix Products
• Table 29 SELECTED DBM PRODUCT AND PERCENTAGE OF DEMINERALIZED BONE MATRIX
  • Accell
  • AlloGro and AlloMatrix
  • Connect Cervical Allograft
  • Coreograft and CorLok
  • DBM Carrier Product
  • DBX
  • Duet Lumbar Allograft
  • DynaCan
  • DynaGraft II
  • Graftech
  • Grafton
  • Opteform
  • OrthoBlast II
  • Osteofil
  • Solo Cervical Allograft
  • VivescOs
  • Xenografts
  • The Market for Allografts
• Table 30 THE U.S. MARKET FOR PRECISION-MACHINED ALLOGRAFTS, THROUGH 2007 ($ MILLIONS)
  • Cell-Based Bone Graft Substitutes
  • Factor-based Bone Graft Substitutes
  • Bone Morphogenic Proteins
  • InductOs
  • InFUSE Bone Graft
  • Ne-Osteo
  • OP-1 Implant
  • Ossigel
  • Skelite
  • Ceramic-based Bone Graft Substitutes
  • Types of Ceramics
  • Alpha-BSM
  • BioGran
  • BioOss
  • BoneSource
  • Calcigen S
  • Collagraft Strip Bone Graft Matrix
  • Conduit TCP Granules
  • IsoTis Products
  • Mimix Bone Substitute Material
  • Norian SRS
  • OsteoGraf
  • Osteoset
  • Osteostim Resorbable Bone Graft Substitute
  • PerioGlas
  • Pro Osteon Implant 500
  • Vitoss
  • Polymer-based Bone Graft Substitutes
  • Bioplant Hard Tissue Replacement
  • Bioplant Hard Tissue Replacement (Continued)
  • Cortoss
  • Healos
  • Immix Extenders and Immix CB
  • Polyactive
  • Poly(lactic-co-glycolic acid) Foam Matrix
  • Poly(propylene) Fumarate
  • Rhakoss
  • The Market for Bone Graft Products
• Table 31 THE WORLDWIDE MARKET FOR BONE REPLACEMENT PRODUCTS, THROUGH 2007 ($ MILLIONS)
• Table 32 THE U.S. MARKET FOR BONE REPLACEMENT PRODUCTS, THROUGH 2007 ($ MILLIONS)
• Figure 9 THE U.S. MARKET FOR BONE REPLACEMENT PRODUCTS, 2001, 2002 AND 2007 ($ MILLIONS)
  • Regenerative Medicine Products in Development for Bone Applications
  • Biologic/Synthetic Grafts
  • Chrysalin
  • BONE GROWTH STIMULATORS
  • Types of Bone Growth Stimulation
  • Semi-invasive Direct Current
  • Invasive Direct Current
  • Pulsing Electromagnetic Fields
  • Marketers of Noninvasive Bone Growth Stimulators
  • EBI, Inc./Biomet
  • Orthofix/Medtronic
  • OrthoLogic/Johnson & Johnson
  • OrthoLogic/Johnson & Johnson (Continued)
  • Smith & Nephew
  • The Market for Noninvasive Bone Growth Stimulators
• Table 33 THE WORLDWIDE MARKET FOR NONINVASIVE BONE GROWTH STIMULATORS, THROUGH 2007 ($ MILLIONS)
• Figure 10 THE WORLDWIDE MARKET FOR NONINVASIVE BONE GROWTH STIMULATORS, THROUGH 2007 ($ MILLIONS)
• Table 34 THE U.S. MARKET FOR NONINVASIVE BONE GROWTH STIMULATORS, THROUGH 2007 ($ MILLIONS)
  • Market Share by Manufacturer
• Figure 11 SHARE BY COMPANY OF THE NONINVASIVE BONE GROWTH STIMULATOR MARKET, U.S., 2002
  • REGENERATIVE PRODUCTS TO TREAT DISEASED AND DAMAGED JOINTS
    • AUTOLOGOUS PRODUCTS
    • BioSeed-C Autologous 3D Chondrocyte Graft
    • Carticel®
    • CellActive Cartilage
    • Collagen Meniscus Implant
    • Immix Chondroflex
    • The Market for Tissue-Engineered Cartilage Products
• Table 35 THE U.S. MARKET FOR TISSUE-ENGINEERED CARTILAGE PRODUCTS, THROUGH 2007 ($ MILLIONS)
  • COMPANIES WITH REGENERATIVE PRODUCTS IN DEVELOPMENT
  • Curis
  • Genzyme Biosurgery
  • Genzyme/Johns Hopkins University
  • IsoTis NV
  • Isto Technologies
  • Millenium Biologix
  • TiGenix NV
  • TiGenix NV (Continued)

• SUPPLIERS OF REGENERATIVE BONE AND JOINT PRODUCTS
• PREMARKET NOTIFICATION-510(K)
  • WHAT IS PREMARKET NOTIFICATION?
  • WHAT IS SUBSTANTIAL EQUIVALENCE?
  • WHO IS REQUIRED TO SUBMIT A 510(K)?
  • WHEN A 510(K) IS REQUIRED
  • WHEN A 501(K) IS NOT REQUIRED
  • THE MODERNIZATION ACT AND THE 510(K) SUBMISSION PROCESS-DIFFERENT TYPES OF SUBMISSIONS FOR DIFFERING SITUATIONS
  • MEDICAL DEVICES REVIEWED BY THE CENTER FOR BIOLOGIC, EVALUATION, RESEARCH
  • THIRD PARTY REVIEW PROGRAM
• REGULATORY ISSUES FOR CELLULAR AND TISSUE-BASED PRODUCTS
  • CHANGES IN THE REGULATION OF DEMINERALIZED BONE PRODUCTS
  • INDUSTRY GROWTH
  • Bankruptcies
  • Regulatory Issues
  • Development Issues
  • Pricing
  • Capital
  • ADVANCED TISSUE SCIENCES
  • ORGANOGENESIS
  • CURIS EXITS THE TISSUE ENGINEERING MARKET
• THE TISSUE-ENGINEERING MARKET IN EUROPE
• THE DEVELOPMENT OF REGENERATIVE MEDICINES IN JAPAN
  • THE DEVELOPMENT ... IN JAPAN (CONTINUED)

• BIOMET ORTHOPEDICS, INC.
  • BUSINESS OVERVIEW
  • FINANCIAL INFORMATION
  • LEADING PRODUCTS
  • CORPORATE STRATEGY
• BIOTISSUE TECHNOLOGIES AG
  • BUSINESS OVERVIEW
  • LEADING PRODUCTS
  • CORPORATE STRATEGY
• CENTERPULSE, INC.
  • BUSINESS OVERVIEW
  • FINANCIAL INFORMATION
  • LEADING PRODUCTS
  • CORPORATE STRATEGY
• CORTEK, INC.
  • BUSINESS OVERVIEW
  • LEADING PRODUCTS
  • CORPORATE STRATEGY
• CURIS, INC.
  • BUSINESS OVERVIEW
  • FINANCIAL INFORMATION
  • LEADING PRODUCTS
  • CORPORATE STRATEGY
  • Development Terminations
  • Reorganization
  • Product Focus
  • Johnson & Johnson Agreements
  • Stryker Agreements
  • Other Agreements
  • Patents
• GENSCI REGENERATION SCIENCES INC.
  • BUSINESS OVERVIEW
  • FINANCIAL INFORMATION
  • LEADING PRODUCTS
  • CORPORATE STRATEGY
• GENZYME BIOSURGERY
  • BUSINESS OVERVIEW
  • FINANCIAL INFORMATION
  • LEADING PRODUCTS
  • CORPORATE STRATEGY
• INTEGRA LIFESCIENCES HOLDINGS CORP.
  • BUSINESS OVERVIEW
  • FINANCIAL INFORMATION
  • LEADING PRODUCTS
  • CORPORATE STRATEGY
• INTERPORE CROSS INTERNATIONAL
  • BUSINESS OVERVIEW
  • FINANCIAL INFORMATION
  • LEADING PRODUCTS
• Table 36 INTERPORE CROSS'S MARKETED ORTHOBIOLOGIC PRODUCTS
• Table 37 INTERPORE CROSS'S NEAR-TERM PRODUCT PIPELINE
  • CORPORATE STRATEGY
  • ISOTIS BV
    • BUSINESS OVERVIEW
    • LEADING PRODUCTS
    • CORPORATE STRATEGY
  • ISTO TECHNOLOGIES, INC.
    • BUSINESS OVERVIEW
    • LEADING PRODUCTS
    • CORPORATE STRATEGY
  • MEDTRONIC, INC.
    • BUSINESS OVERVIEW
    • FINANCIAL INFORMATION
    • LEADING PRODUCTS
    • CORPORATE STRATEGY
  • MILLENIUM BIOLOGIX INC.
    • BUSINESS OVERVIEW
    • LEADING PRODUCTS
    • CORPORATE STRATEGY
  • NEUCOLL INC.
    • BUSINESS OVERVIEW
    • LEADING PRODUCTS
    • CORPORATE STRATEGY
  • ORQUEST, INC.
    • BUSINESS OVERVIEW
    • LEADING PRODUCTS
• Table 38 ORQUEST'S PRODUCT PIPELINE
  • CORPORATE STRATEGY
  • ORTHOFIX INTERNATIONAL N.V.
    • BUSINESS OVERVIEW
    • FINANCIAL INFORMATION
    • LEADING PRODUCTS
    • Leading Products (Continued)
    • CORPORATE STRATEGY
  • ORTHOLOGIC CORP.
    • BUSINESS OVERVIEW
    • FINANCIAL INFORMATION
    • LEADING PRODUCTS
    • OL1000
    • SpinaLogic
    • Chrysalin
    • CORPORATE STRATEGY
  • ORTHOVITA, INC.
    • BUSINESS OVERVIEW
    • FINANCIAL INFORMATION
    • LEADING PRODUCTS
    • Leading Products (Continued)
• Table 39 ORTHOVITA'S PRODUCT PIPELINE
  • CORPORATE STRATEGY
  • OSTEOBIOLOGICS, INC.
    • BUSINESS OVERVIEW
    • LEADING PRODUCTS
    • CORPORATE STRATEGY
• Table 40 OSTEOBIOLOGICS' PATENT PORTFOLIO
  • OSTEOTECH INC.
    • BUSINESS OVERVIEW
    • FINANCIAL INFORMATION
    • LEADING PRODUCTS
    • CORPORATE STRATEGY
    • Corporate Strategy (Continued)
    • Corporate Strategy (Continued)
  • REGEN BIOLOGICS, INC.
    • BUSINESS OVERVIEW
    • LEADING PRODUCTS
    • CORPORATE STRATEGY
  • STRYKER CORP.
    • BUSINESS OVERVIEW
    • FINANCIAL INFORMATION
    • LEADING PRODUCTS
    • CORPORATE STRATEGY
  • TIGENIX N.V.
    • BUSINESS OVERVIEW
    • LEADING PRODUCTS
    • CORPORATE STRATEGY
  • WRIGHT MEDICAL GROUP, INC.
    • FINANCIAL INFORMATION
    • LEADING PRODUCTS
    • CORPORATE STRATEGY

LIST OF TABLES

Summary Table: THE U.S. MARKET FOR REGENERATIVE MEDICINE PRODUCTS USED IN BONE AND JOINT APPLICATIONS, THROUGH 2007 ($ MILLIONS)

Table 1 THE WORLDWIDE MARKET FOR DRUGS TO TREAT OSTEOPOROSIS, THROUGH 2007 ($ MILLIONS)

Table 2 THE WORLDWIDE MARKET FOR DRUGS TO TREAT PAGET'S DISEASE, THROUGH 2007 ($ MILLIONS)

Table 3 HIP FRACTURE VOLUMES, WORLDWIDE, THROUGH 2007

Table 4 HIP FRACTURE VOLUMES, U.S., THROUGH 2007

Table 5 HIP REPLACEMENT PROCEDURE VOLUMES, U.S., THROUGH 2007

Table 6 HIP REPLACEMENT PROCEDURE VOLUMES IN SIX STATES, 2001

Table 7 THE HIP REPLACEMENT MARKET, WORLDWIDE, THROUGH 2007 ($ MILLIONS)

Table 8 THE HIP REPLACEMENT MARKET, U.S., THROUGH 2007 ($ MILLIONS)

Table 9 KNEE REPLACEMENT PROCEDURE VOLUMES, WORLDWIDE, THROUGH 2007

Table 10 KNEE REPLACEMENT PROCEDURE VOLUMES, U.S., THROUGH 2007

Table 11 THE KNEE REPLACEMENT MARKET, WORLDWIDE, THROUGH 2007 ($ MILLIONS)

Table 12 THE KNEE REPLACEMENT MARKET, U.S., THROUGH 2007 ($ MILLIONS)

Table 13 THE MARKET FOR UNICONDYLAR KNEE REPLACEMENT, U.S., THROUGH 2007 ($ MILLIONS)

Table 14 SPINAL FUSION PROCEDURE VOLUMES, WORLDWIDE, THROUGH 2007

Table 15 SPINAL FUSION PROCEDURE VOLUMES, U.S., THROUGH 2007

Table 16 LUMBAR SPINAL FUSION PROCEDURE VOLUMES, U.S., THROUGH 2007

Table 17 POSTERIOR LUMBAR SPINAL FUSION PROCEDURE VOLUMES, U.S., THROUGH 2007

Table 18 CERVICAL SPINAL FUSION PROCEDURE VOLUMES, U.S., THROUGH 2007

Table 19 THE MARKET FOR INTERBODY FUSION DEVICE IMPLANTATION PROCEDURES, WORLDWIDE, THROUGH 2007 ($ MILLIONS)

Table 20 INTERBODY FUSION DEVICE IMPLANTATION PROCEDURE VOLUMES, U.S., THROUGH 2007

Table 21 PREVALENCE OF RHEUMATOID ARTHRITIS, U.S., THROUGH 2007

Table 22 THERAPEUTIC ANTIBODY PRODUCTS IN PHASE II OR LATER DEVELOPMENT FOR THE TREATMENT OF RHEUMATOID ARTHRITIS

Table 23 THE MARKET FOR DISEASE-MODIFYING ANTI-ARTHRITIC DRUGS TO TREAT RHEUMATOID ARTHRITIS, WORLDWIDE, THROUGH 2007 ($ MILLIONS)

Table 24 NUMBER OF 2003 TRIALS OF DRUGS TO TREAT RHEUMATOID ARTHRITIS BY MECHANISM OF ACTION

Table 25 BONE GRAFT PROCEDURE VOLUMES BY APPLICATION, U.S., THROUGH 2007

Table 26 BONE GRAFT PROCEDURE VOLUMES BY TYPE OF GRAFT, U.S., THROUGH 2007

Table 27 COMPARISON OF BONE GRAFT MATERIALS

Table 28 TYPES OF SUBSTITUTE BONE GRAFTS

Table 29 SELECTED DBM PRODUCT AND PERCENTAGE OF DEMINERALIZED BONE MATRIX

Table 30 THE U.S. MARKET FOR PRECISION-MACHINED ALLOGRAFTS, THROUGH 2007 ($ MILLIONS)

Table 31 THE WORLDWIDE MARKET FOR BONE REPLACEMENT PRODUCTS, THROUGH 2007 ($ MILLIONS)

Table 32 THE U.S. MARKET FOR BONE REPLACEMENT PRODUCTS, THROUGH 2007 ($ MILLIONS)

Table 33 THE WORLDWIDE MARKET FOR NONINVASIVE BONE GROWTH STIMULATORS, THROUGH 2007 ($ MILLIONS)

Table 34 THE U.S. MARKET FOR NONINVASIVE BONE GROWTH STIMULATORS, THROUGH 2007 ($ MILLIONS)

Table 35 THE U.S. MARKET FOR TISSUE-ENGINEERED CARTILAGE PRODUCTS, THROUGH 2007 ($ MILLIONS)

Table 36 INTERPORE CROSS'S MARKETED ORTHOBIOLOGIC PRODUCTS

Table 37 INTERPORE CROSS'S NEAR-TERM PRODUCT PIPELINE

Table 38 ORQUEST'S PRODUCT PIPELINE

Table 39 ORTHOVITA'S PRODUCT PIPELINE

Table 40 OSTEOBIOLOGICS' PATENT PORTFOLIO  

LIST OF FIGURES

Summary Figure: THE U.S. MARKET FOR REGENERATIVE MEDICINE PRODUCTS USED IN BONE AND JOINT APPLICATIONS, 2001, 2002 AND 2007 ($ MILLIONS)

Figure 1 THE U.S. MUSCULOSKELETAL PRODUCTS MARKET, 2002

Figure 2 THE U.S. RECONSTRUCTIVE DEVICE MARKET, 2002

Figure 3 HIP REPLACEMENT PROCEDURE VOLUMES, U.S., 2001, 2002 AND 2007

Figure 4 KNEE REPLACEMENT PROCEDURE VOLUMES, U.S., 2001, 2002 AND 2007

Figure 5 SPINAL FUSION PROCEDURE VOLUMES, U.S., THROUGH 2007

Figure 6 THE U.S. SPINAL PRODUCTS MARKET, 2002

Figure 7 THE MARKET FOR DISEASE-MODIFYING ANTI-ARTHRITIC DRUGS TO TREAT RHEUMATOID ARTHRITIS, WORLDWIDE, 2001, 2002 AND 2007 ($ MILLIONS)

Figure 8 BONE GRAFT PROCEDURE VOLUMES BY TYPE OF GRAFT, U.S., 2001, 2002 AND 2007

Figure 9 THE U.S. MARKET FOR BONE REPLACEMENT PRODUCTS, 2001, 2002 AND 2007 ($ MILLIONS)

Figure 10 THE WORLDWIDE MARKET FOR NONINVASIVE BONE GROWTH STIMULATORS, THROUGH 2007 ($ MILLIONS)

Figure 11 SHARE BY COMPANY OF THE NONINVASIVE BONE GROWTH STIMULATOR MARKET, U.S., 2002